The FDA approved Novo Nordisk's higher-dose 7.2 mg Wegovy injection on March 19, tripling the previous maximum dose of 2.4 mg. In a phase 3 trial, patients with obesity lost an average of 20.7% of their body weight after 72 weeks, while those with obesity and Type 2 diabetes lost 14.1%.
The approval marks the first use of the FDA's new national priority voucher program, which cuts drug review times to one to two months. Novo Nordisk plans to launch the higher dose in April as it fights to reclaim market share from Eli Lilly's competing GLP-1 drugs.
Side effects were reported in over 70% of patients on the high dose, including nausea, vomiting, and constipation, compared to 60% on the standard dose and 43% on placebo.
